KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Cash from Operations (2017 - 2025)

Historic Cash from Operations for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to -$12.6 million.

  • Aquestive Therapeutics' Cash from Operations fell 647.31% to -$12.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.5 million, marking a year-over-year decrease of 4746.87%. This contributed to the annual value of -$35.8 million for FY2024, which is 46048.59% down from last year.
  • Latest data reveals that Aquestive Therapeutics reported Cash from Operations of -$12.6 million as of Q3 2025, which was down 647.31% from -$7.9 million recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' Cash from Operations peaked at $8.8 million during Q1 2023, and registered a low of -$23.4 million during Q1 2025.
  • Its 5-year average for Cash from Operations is -$6.8 million, with a median of -$7.9 million in 2023.
  • Per our database at Business Quant, Aquestive Therapeutics' Cash from Operations surged by 20440.39% in 2022 and then tumbled by 40617.81% in 2024.
  • Aquestive Therapeutics' Cash from Operations (Quarter) stood at -$8.1 million in 2021, then surged by 204.4% to $8.4 million in 2022, then tumbled by 158.72% to -$4.9 million in 2023, then plummeted by 31.3% to -$6.5 million in 2024, then plummeted by 94.93% to -$12.6 million in 2025.
  • Its last three reported values are -$12.6 million in Q3 2025, -$7.9 million for Q2 2025, and -$23.4 million during Q1 2025.